Cabaletta Bio (NASDAQ:CABA) Rating Reiterated by HC Wainwright

HC Wainwright restated their buy rating on shares of Cabaletta Bio (NASDAQ:CABA) in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has a $30.00 price objective on the stock. HC Wainwright also issued estimates for Cabaletta Bio’s FY2028 earnings at $4.16 EPS.

Several other equities analysts have also recently issued reports on CABA. Cantor Fitzgerald reissued an overweight rating and issued a $50.00 price objective on shares of Cabaletta Bio in a research note on Friday, April 5th. Wells Fargo & Company boosted their price target on shares of Cabaletta Bio from $34.00 to $35.00 and gave the stock an overweight rating in a research note on Friday, March 22nd. Jefferies Financial Group started coverage on shares of Cabaletta Bio in a research report on Monday, February 5th. They issued a buy rating and a $36.00 price objective for the company. Finally, Citigroup lifted their price objective on Cabaletta Bio from $26.00 to $30.00 and gave the company a buy rating in a report on Thursday, April 4th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Cabaletta Bio currently has an average rating of Buy and an average target price of $34.33.

Cabaletta Bio Stock Down 2.1 %

CABA stock traded down $0.27 during trading on Thursday, hitting $12.35. The company had a trading volume of 944,850 shares, compared to its average volume of 1,045,785. The firm has a 50-day moving average price of $15.46 and a 200-day moving average price of $18.64. The firm has a market cap of $578.10 million, a PE ratio of -7.22 and a beta of 2.52. Cabaletta Bio has a 1-year low of $9.02 and a 1-year high of $26.35.

Cabaletta Bio (NASDAQ:CABA) last announced its earnings results on Thursday, March 21st. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.07). Sell-side analysts anticipate that Cabaletta Bio will post -1.82 earnings per share for the current year.

Institutional Trading of Cabaletta Bio

A number of institutional investors have recently bought and sold shares of CABA. Macroview Investment Management LLC acquired a new position in shares of Cabaletta Bio during the 4th quarter worth $26,000. Tower Research Capital LLC TRC increased its holdings in Cabaletta Bio by 65.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,623 shares of the company’s stock valued at $60,000 after acquiring an additional 1,042 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in Cabaletta Bio during the third quarter worth about $63,000. Amalgamated Bank lifted its holdings in shares of Cabaletta Bio by 24.7% in the third quarter. Amalgamated Bank now owns 4,648 shares of the company’s stock valued at $71,000 after purchasing an additional 922 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Cabaletta Bio in the fourth quarter valued at approximately $113,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.